Ubiquitin in cell-cycle regulation and dysregulation in cancer

Natalie A. Borg, Vishva M. Dixit

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Uncontrolled cell proliferation and genomic instability are common features of cancer and can arise from, respectively, the loss of cell-cycle control and defective checkpoints. Ubiquitin-mediated proteolysis, ultimately executed by ubiquitin-ligating enzymes (E3s), plays a key part in cell-cycle regulation and is dominated by two multisubunit E3s, the anaphase-promoting complex (or cyclosome) (APC/C) and SKP1–cullin-1–F-box (SCF) complex. We highlight the role of APC/C and the SCF bound to F-box proteins, FBXW7, SKP2, and β-TrCP, in regulating the abundance of select fundamental proteins, primarily during the cell cycle, that are associated with human cancer. The clinical success of the first proteasome inhibitor, bortezomib, in treating multiple myeloma and mantle-cell lymphoma set the precedent for viewing the ubiquitin–proteasome system as a druggable target for cancer. Given that there are more E3s than kinases, selective, small-molecule E3 inhibitors have the potential of opening up another dimension in the therapeutic armamentarium for the treatment of cancer.
Original languageEnglish
Pages (from-to)59-77
Number of pages19
JournalAnnual Review of Cancer Biology
Volume1
DOIs
Publication statusPublished - Mar 2017

Keywords

  • ubiquitin
  • proteasome
  • APC/C
  • SCF
  • E3
  • cell cycle
  • cancer

Cite this

@article{c25590c1490c458aae6a49c6740156be,
title = "Ubiquitin in cell-cycle regulation and dysregulation in cancer",
abstract = "Uncontrolled cell proliferation and genomic instability are common features of cancer and can arise from, respectively, the loss of cell-cycle control and defective checkpoints. Ubiquitin-mediated proteolysis, ultimately executed by ubiquitin-ligating enzymes (E3s), plays a key part in cell-cycle regulation and is dominated by two multisubunit E3s, the anaphase-promoting complex (or cyclosome) (APC/C) and SKP1–cullin-1–F-box (SCF) complex. We highlight the role of APC/C and the SCF bound to F-box proteins, FBXW7, SKP2, and β-TrCP, in regulating the abundance of select fundamental proteins, primarily during the cell cycle, that are associated with human cancer. The clinical success of the first proteasome inhibitor, bortezomib, in treating multiple myeloma and mantle-cell lymphoma set the precedent for viewing the ubiquitin–proteasome system as a druggable target for cancer. Given that there are more E3s than kinases, selective, small-molecule E3 inhibitors have the potential of opening up another dimension in the therapeutic armamentarium for the treatment of cancer.",
keywords = "ubiquitin, proteasome, APC/C, SCF, E3, cell cycle, cancer",
author = "Borg, {Natalie A.} and Dixit, {Vishva M.}",
year = "2017",
month = "3",
doi = "10.1146/annurev-cancerbio-040716-075607",
language = "English",
volume = "1",
pages = "59--77",
journal = "Annual Review of Cancer Biology",
issn = "2472-3428",
publisher = "Annual Reviews",

}

Ubiquitin in cell-cycle regulation and dysregulation in cancer. / Borg, Natalie A.; Dixit, Vishva M.

In: Annual Review of Cancer Biology, Vol. 1, 03.2017, p. 59-77.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Ubiquitin in cell-cycle regulation and dysregulation in cancer

AU - Borg, Natalie A.

AU - Dixit, Vishva M.

PY - 2017/3

Y1 - 2017/3

N2 - Uncontrolled cell proliferation and genomic instability are common features of cancer and can arise from, respectively, the loss of cell-cycle control and defective checkpoints. Ubiquitin-mediated proteolysis, ultimately executed by ubiquitin-ligating enzymes (E3s), plays a key part in cell-cycle regulation and is dominated by two multisubunit E3s, the anaphase-promoting complex (or cyclosome) (APC/C) and SKP1–cullin-1–F-box (SCF) complex. We highlight the role of APC/C and the SCF bound to F-box proteins, FBXW7, SKP2, and β-TrCP, in regulating the abundance of select fundamental proteins, primarily during the cell cycle, that are associated with human cancer. The clinical success of the first proteasome inhibitor, bortezomib, in treating multiple myeloma and mantle-cell lymphoma set the precedent for viewing the ubiquitin–proteasome system as a druggable target for cancer. Given that there are more E3s than kinases, selective, small-molecule E3 inhibitors have the potential of opening up another dimension in the therapeutic armamentarium for the treatment of cancer.

AB - Uncontrolled cell proliferation and genomic instability are common features of cancer and can arise from, respectively, the loss of cell-cycle control and defective checkpoints. Ubiquitin-mediated proteolysis, ultimately executed by ubiquitin-ligating enzymes (E3s), plays a key part in cell-cycle regulation and is dominated by two multisubunit E3s, the anaphase-promoting complex (or cyclosome) (APC/C) and SKP1–cullin-1–F-box (SCF) complex. We highlight the role of APC/C and the SCF bound to F-box proteins, FBXW7, SKP2, and β-TrCP, in regulating the abundance of select fundamental proteins, primarily during the cell cycle, that are associated with human cancer. The clinical success of the first proteasome inhibitor, bortezomib, in treating multiple myeloma and mantle-cell lymphoma set the precedent for viewing the ubiquitin–proteasome system as a druggable target for cancer. Given that there are more E3s than kinases, selective, small-molecule E3 inhibitors have the potential of opening up another dimension in the therapeutic armamentarium for the treatment of cancer.

KW - ubiquitin

KW - proteasome

KW - APC/C

KW - SCF

KW - E3

KW - cell cycle

KW - cancer

U2 - 10.1146/annurev-cancerbio-040716-075607

DO - 10.1146/annurev-cancerbio-040716-075607

M3 - Review Article

VL - 1

SP - 59

EP - 77

JO - Annual Review of Cancer Biology

JF - Annual Review of Cancer Biology

SN - 2472-3428

ER -